Author

R. Choque-Guevara

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Organism:rat· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Organism:zebrafish· 1

Frequent Co-Authors

A. Agurto-Arteaga· 2 shared A. Montalvan· 2 shared A. Poma-Acevedo· 2 shared D. Rios-Matos· 2 shared D. Villanueva-Perez· 2 shared G. Isasi-Rivas· 2 shared I. Ramirez-Ortiz· 2 shared K. Gutierrez-Manchay· 2 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Agurto-Arteaga

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A recombinant SARS-CoV-2 RBD antigen expressed in insect cells elicits immunogenicity and confirms safety in animal models

R. Choque-Guevara, A. Poma-Acevedo, R. Montesinos-Millan, D. Rios-Matos, K. Gutierrez-Manchay, A. Montalvan, S. Quinones-Garcia, M. d. G. Cauti-Mendoza, A. Agurto-Arteaga, I. Ramirez-Ortiz, M. Criollo-Orozco, E. Huaccachi-Gonzales, Y. K. R. Lazaro, N. Perez-Martinez, G. Isasi-Rivas, , COVID-19 Working Group in Peru

This paper evaluates a recombinant SARS-CoV-2 RBD antigen expressed in insect cells for immunogenicity and safety in mice and hamsters.

bioRxiv · Nov 26, 2021 · PreprintImmunology

Development and pre-clinical evaluation of Newcastle disease virus-vectored SARS-CoV-2 intranasal vaccine candidate

M. Fernandez-Diaz, K. Calderon, A. Rojas-Neyra, V. N. Vakharia, R. Choque-Guevara, A. Montalvan, A. Poma-Acevedo, D. Rios-Matos, A. Agurto-Arteaga, M. D. G. Cauti-Mendoza, N. Perez-Martinez, G. Isasi-Rivas, L. Tataje-Lavanda, M. Palomino, H. Bailon, , Salguedo-Bohorqu

This paper develops and evaluates an NDV-vectored SARS-CoV-2 intranasal vaccine candidate, showing safety, immunogenicity, and efficacy in animal models.

bioRxiv · Mar 7, 2021 · PreprintImmunology